Market Overview

From Biogen Call: Eloctate Could Be Facing Potential Approval Delay

Related BIIB
2 Columbia Growth Funds Notch Impressive Three-Month Performance
Biogen Idec, Inc. Suddenly Struggling To Keep Up With The Biotech Joneses
Don't Panic Over Recent Tech Turmoil (Fox Business)

Posted-In: News FDA


Related Articles (BIIB)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters